Literature DB >> 26522456

Insulin-like growth factor binding proteins 4-6.

Leon A Bach1.   

Abstract

Insulin-like growth factor binding proteins (IGFBPs) 4-6 have important roles as modulators of IGF actions. IGFBP-4 and IGFBP-6 predominantly inhibit IGF actions, whereas IGFBP-5 may enhance these actions under some circumstances. IGFBP-6 is unique among the IGFBPs for its marked IGF-II binding preference. IGFBPs 4-6 are found in the circulation as binary complexes with IGFs that can enter tissues. Additionally, about half of the circulating IGFBP-5 is found in ternary complexes with IGFs and an acid labile subunit; this high molecular complex cannot leave the circulation and acts as an IGF reservoir. IGFBPs 4-6 also have IGF-independent actions. These IGFBPs are regulated in a cell-specific manner and their dysregulation may play a role in a range of diseases including cancer. However, there is no clear clinical indication for measuring serum levels of these IGFBPs at present.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  binding protein; cellular action; insulin-like growth factor; protein structure; regulation

Mesh:

Substances:

Year:  2015        PMID: 26522456     DOI: 10.1016/j.beem.2015.06.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  9 in total

1.  Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis.

Authors:  C Pascucci; R V De Biase; D Savi; S Quattrucci; A M Isidori; C Lubrano; L Gnessi; A Lenzi
Journal:  J Endocrinol Invest       Date:  2017-11-02       Impact factor: 4.256

2.  Large-scale analysis of variation in the insulin-like growth factor family in humans reveals rare disease links and common polymorphisms.

Authors:  Peter Rotwein
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

3.  Effect of Anthocyanins Supplementation on Serum IGFBP-4 Fragments and Glycemic Control in Patients with Fasting Hyperglycemia: A Randomized Controlled Trial.

Authors:  Liping Yang; Zhaomin Liu; Wenhua Ling; Li Wang; Changyi Wang; Jianping Ma; Xiaolin Peng; Jianying Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2020-09-28       Impact factor: 3.168

4.  Low expression of IGFBP4 and TAGLN accelerate the poor overall survival of osteosarcoma.

Authors:  Yue Xi; Jianlin Liu; Gufeng Shen
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

Review 5.  Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis.

Authors:  Biao Zhang; Chao-Qun Hong; Yu-Hao Luo; Lai-Feng Wei; Yun Luo; Yu-Hui Peng; Yi-Wei Xu
Journal:  Cancer Med       Date:  2022-05-11       Impact factor: 4.711

6.  Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?

Authors:  Alessia Alunno; Onelia Bistoni; Mirko Manetti; Giacomo Cafaro; Valentina Valentini; Elena Bartoloni; Roberto Gerli; Arcangelo Liso
Journal:  Front Immunol       Date:  2017-05-18       Impact factor: 7.561

Review 7.  Insulin-Like Growth Factor Binding Proteins and IGFBP Proteases: A Dynamic System Regulating the Ovarian Folliculogenesis.

Authors:  Sabine Mazerbourg; Philippe Monget
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-29       Impact factor: 5.555

8.  MiR-137 inhibited cell proliferation and migration of vascular smooth muscle cells via targeting IGFBP-5 and modulating the mTOR/STAT3 signaling.

Authors:  Jin Pan; Kai Li; Wei Huang; Xiaoqing Zhang
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

9.  A Draft Map of the Human Ovarian Proteome for Tissue Engineering and Clinical Applications.

Authors:  Emna Ouni; Didier Vertommen; Maria Costanza Chiti; Marie-Madeleine Dolmans; Christiani A Amorim
Journal:  Mol Cell Proteomics       Date:  2018-02-23       Impact factor: 5.911

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.